Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib as Maintenance Therapy for IDH1-mutant AML Following Stem Cell Transplantation
NCT06707493Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivosidenib in acute myeloid leukemia (AML), sponsored by Massachusetts General Hospital. Started Jan 2026; status: recruiting.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06707493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06707493.